Is it safe to add celecoxib (Celebrex) 200 mg and pregabalin (Lyrica) 50 mg to a patient already taking guanfacine 2 mg three times daily, citalopram 20 mg daily, alprazolam 2 mg twice daily, and lamotrigine 150 mg daily?

Safety Assessment: Adding Celecoxib and Pregabalin to Current Polypharmacy Regimen

Direct Answer

Adding celecoxib 200 mg and pregabalin 50 mg to this patient's current regimen requires extreme caution due to significant CNS depression risk from combining pregabalin with existing alprazolam and citalopram, though no absolute pharmacokinetic contraindications exist.

---

Critical Drug-Drug Interaction Concerns

High-Risk CNS Depression

The 2019 AGS Beers Criteria explicitly warns against concurrent use of three or more CNS-active agents due to increased fall risk and cognitive impairment. 1 This patient is already on:

• Alprazolam 2 mg BID (benzodiazepine)
• Citalopram 20 mg (antidepressant)
• Guanfacine 2 mg TID (centrally-acting alpha-2 agonist)
• Lamotrigine 150 mg (antiepileptic)

Adding pregabalin would create a fifth CNS-active medication, substantially exceeding safe polypharmacy thresholds. 1

Specific Pregabalin Interactions

The AGS Beers Criteria specifically recommends avoiding concurrent use of opioids with gabapentinoids (pregabalin/gabapentin) due to additive CNS and respiratory depression. 1 While this patient isn't on opioids currently, the FDA label confirms that pregabalin co-administered with lorazepam (a benzodiazepine similar to alprazolam) produces additive effects on cognitive and gross motor functioning. 2

The FDA explicitly states: "Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when LYRICA was co-administered with these drugs." 2

---

Pharmacokinetic Safety Profile

Favorable Aspects

Pregabalin has minimal drug-drug interaction potential from a pharmacokinetic standpoint:

• No CYP450 enzyme inhibition or induction 2
• No protein binding displacement 2
• Predominantly renal excretion with <2% metabolism 2
• No interactions with lamotrigine, carbamazepine, valproic acid, or phenytoin 2

Celecoxib similarly shows no significant interactions with SSRIs (citalopram) or benzodiazepines based on available evidence. 3

Lamotrigine Compatibility

Pregabalin does not affect lamotrigine plasma concentrations, making this combination pharmacokinetically safe. 2 This is critical since lamotrigine has narrow therapeutic windows with other anticonvulsants like valproic acid. 4

---

Clinical Risk Stratification

Major Concerns (Must Address)

1. Sedation and cognitive impairment: The combination of alprazolam, guanfacine, citalopram, and pregabalin creates substantial risk for:

   • Somnolence and dizziness (common pregabalin side effects) 5
   • Falls (especially if patient is elderly) 1
   • Impaired motor coordination 2

2. Respiratory depression risk: While the FDA notes "no clinically important effects on respiration" in studies, this was not tested with benzodiazepines at therapeutic doses. 2

Moderate Concerns

1. Pregabalin starting dose: The proposed 50 mg daily is below standard starting doses (75-150 mg/day for neuropathic pain). 2 However, this conservative approach is appropriate given polypharmacy burden.

2. Dose escalation monitoring: Pregabalin requires incremental titration with "intervals long enough to allow monitoring of effects," particularly critical in polypharmacy. 5

---

Specific Recommendations

If Proceeding (Risk Mitigation Strategy)

Consider this addition ONLY if:

1. Reduce alprazolam dose by 25-50% when initiating pregabalin to offset additive CNS depression (clinical judgment, not guideline-specified but medically prudent given 1, 2)

2. Start pregabalin at 25 mg daily (lower than proposed 50 mg) given the polypharmacy burden, despite this being below FDA-labeled starting doses 2

3. Titrate extremely slowly (no faster than weekly increases of 25 mg) while monitoring for:

   • Sedation/somnolence
   • Dizziness
   • Mental clouding
   • Gait instability 5

4. Celecoxib 200 mg is pharmacokinetically safe and can be initiated without dose adjustment 3, 6, 7

5. Assess renal function before pregabalin initiation, as dose adjustment is required for CrCl <60 mL/min 2

Alternative Approach (Safer)

Strongly consider deprescribing alprazolam before adding pregabalin:

• Pregabalin has anxiolytic properties that may partially substitute for benzodiazepine effects
• This reduces total CNS medication burden from 5 to 4 agents
• Taper alprazolam slowly (0.25-0.5 mg every 1-2 weeks) while monitoring anxiety symptoms

---

Monitoring Parameters

Essential monitoring after initiation:

• Weekly assessment for first month: sedation, falls, cognitive changes 5, 1
• Pain scores to justify continued use
• Functional status and activities of daily living
• Consider formal fall risk assessment if patient >65 years 1

---

Bottom Line

The combination is not absolutely contraindicated from a pharmacokinetic perspective, but carries substantial pharmacodynamic risk due to CNS polypharmacy. 1, 2 The safest approach is alprazolam dose reduction or discontinuation before pregabalin initiation, with very conservative pregabalin dosing (starting 25 mg daily, not 50 mg) and close monitoring for CNS adverse effects. Celecoxib poses minimal additional risk and can be added safely. 3, 6, 7